All In Biotech

Drug Trial Radar · NCT04668352

A Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly

Last checked: Nov 19, 2026Latest source record: Jun 23, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,024 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,024

Actual

Start

Apr 15, 2019

Primary completion

Dec 2, 2019

Study completion Dec 2, 2019

Sponsor

Lead sponsor
Restorbio Inc.Industry
Sponsor type
Industry
First posted
Dec 16, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To determine if RTB101 as compared to placebo decreases the percentage of subjects with clinically symptomatic respiratory illness (with or without an associated laboratory-confirmed pathogen) through Week 16.

Conditions

  • Respiratory Tract Infections

Interventions

  • DactolisibDrug

    TORC1 inhibitor

  • PlaceboOther

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects With Clinically Symptomatic Respiratory IllnessTime frame: Week 0-16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • P3 Research Ltd.

    Wellington, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.